An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
ABSTRACT: Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in deve...
- Autores:
-
Buendía Rodrígez, Jefferson Antonio
Vallejos, Carlos
Pichón Rivière, Andrés
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2013
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/35721
- Acceso en línea:
- https://hdl.handle.net/10495/35721
- Palabra clave:
- Neoplasias de la Mama
Breast Neoplasms
Factor de Crecimiento Epidérmico
Epidermal Growth Factor
Trastuzumab
Antineoplásicos
Antineoplastic Agents
Costo - Efectividad
Cost effectiveness
Colombia
Colombia
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by-nc-nd/4.0/
| id |
UDEA2_df9f38edce07fd188298db5b114ded3c |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/35721 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| dc.title.translated.spa.fl_str_mv |
Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2- positivo en Colombia |
| title |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| spellingShingle |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia Neoplasias de la Mama Breast Neoplasms Factor de Crecimiento Epidérmico Epidermal Growth Factor Trastuzumab Antineoplásicos Antineoplastic Agents Costo - Efectividad Cost effectiveness Colombia Colombia |
| title_short |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| title_full |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| title_fullStr |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| title_full_unstemmed |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| title_sort |
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia |
| dc.creator.fl_str_mv |
Buendía Rodrígez, Jefferson Antonio Vallejos, Carlos Pichón Rivière, Andrés |
| dc.contributor.author.none.fl_str_mv |
Buendía Rodrígez, Jefferson Antonio Vallejos, Carlos Pichón Rivière, Andrés |
| dc.contributor.researchgroup.spa.fl_str_mv |
Grupo de Investigación en Farmacología y Toxicología |
| dc.subject.decs.none.fl_str_mv |
Neoplasias de la Mama Breast Neoplasms Factor de Crecimiento Epidérmico Epidermal Growth Factor Trastuzumab Antineoplásicos Antineoplastic Agents |
| topic |
Neoplasias de la Mama Breast Neoplasms Factor de Crecimiento Epidérmico Epidermal Growth Factor Trastuzumab Antineoplásicos Antineoplastic Agents Costo - Efectividad Cost effectiveness Colombia Colombia |
| dc.subject.lemb.none.fl_str_mv |
Costo - Efectividad Cost effectiveness Colombia |
| dc.subject.proposal.spa.fl_str_mv |
Colombia |
| description |
ABSTRACT: Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing countries. This study assesses the cost-effectiveness of adjuvant trastuzumab treatment in Colombia.Methods: A Markov health-state transition model was built to estimate clinical and economic outcomes in HER2-positive breast cancer with or without 12 months trastuzumab adjuvant chemotherapy over a lifetime perspective with annual transition cycles. The model incorporated five health states (disease-free, local recurrence, distant recurrence, cardiac failure, and death). Baseline event rates and 3-year hazard ratio (HR=0.51, IC 95% 0.44–0.59; p<0.0001) were derived from 4-year follow up of the N9831 and NSABP B-31 trial. Costs and utility weights were obtained from the literature and were discounted by 5% annually.Results: The model showed that the utilization of adjuvant trastuzumab treatment in early breast cancer can prolong 0.80 quality-adjusted life-years (QALY), compared with standard chemotherapy, an incremental cost-effectiveness ratio (ICER) of US$ 71,491 per QALY gained.Conclusion: The results suggest that 1-year adjuvant Trastuzumab treatment is not cost-effective in Colombia, using the definition of WHO cost-effectiveness threshold of 3 times GDP per capita. |
| publishDate |
2013 |
| dc.date.issued.none.fl_str_mv |
2013 |
| dc.date.accessioned.none.fl_str_mv |
2023-06-30T12:13:25Z |
| dc.date.available.none.fl_str_mv |
2023-06-30T12:13:25Z |
| dc.type.spa.fl_str_mv |
Artículo de investigación |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.coarversion.none.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Buendía JA, Vallejos C, Pichón-Rivière A. Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2- positivo en Colombia. biomedica [Internet]. 1 de septiembre de 2013 [citado 30 de junio de 2023];33(3):411-7. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/832 |
| dc.identifier.issn.none.fl_str_mv |
0120-4157 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/35721 |
| dc.identifier.doi.none.fl_str_mv |
10.7705/biomedica.v33i3.832 |
| dc.identifier.eissn.none.fl_str_mv |
2590-7379 |
| identifier_str_mv |
Buendía JA, Vallejos C, Pichón-Rivière A. Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2- positivo en Colombia. biomedica [Internet]. 1 de septiembre de 2013 [citado 30 de junio de 2023];33(3):411-7. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/832 0120-4157 10.7705/biomedica.v33i3.832 2590-7379 |
| url |
https://hdl.handle.net/10495/35721 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Biomédica |
| dc.relation.citationendpage.spa.fl_str_mv |
417 |
| dc.relation.citationissue.spa.fl_str_mv |
3 |
| dc.relation.citationstartpage.spa.fl_str_mv |
411 |
| dc.relation.citationvolume.spa.fl_str_mv |
9 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Biomédica |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
7 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Instituto Nacional de Salud |
| dc.publisher.place.spa.fl_str_mv |
Bogotá, Colombia |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/01d2bfc5-4178-4e97-b2df-c3f2dc453283/download https://bibliotecadigital.udea.edu.co/bitstreams/a385a91b-298a-4985-a257-2bf7a615631d/download https://bibliotecadigital.udea.edu.co/bitstreams/b77670b1-9ff5-4cbb-b9a3-83cedb153e73/download https://bibliotecadigital.udea.edu.co/bitstreams/cebe356d-8f02-4c37-9dc3-c72247f15c57/download https://bibliotecadigital.udea.edu.co/bitstreams/fca94d09-d560-4c31-8806-97b42954ce53/download |
| bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 673393701c41ce58c46664b5e441d04e b88b088d9957e670ce3b3fbe2eedbc13 8bd47bfafd6e60c330197d8cdd7d5261 cc054d4caaeaeff98218d9486504bfb1 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052608522813440 |
| spelling |
Buendía Rodrígez, Jefferson AntonioVallejos, CarlosPichón Rivière, AndrésGrupo de Investigación en Farmacología y Toxicología2023-06-30T12:13:25Z2023-06-30T12:13:25Z2013Buendía JA, Vallejos C, Pichón-Rivière A. Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2- positivo en Colombia. biomedica [Internet]. 1 de septiembre de 2013 [citado 30 de junio de 2023];33(3):411-7. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/8320120-4157https://hdl.handle.net/10495/3572110.7705/biomedica.v33i3.8322590-7379ABSTRACT: Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing countries. This study assesses the cost-effectiveness of adjuvant trastuzumab treatment in Colombia.Methods: A Markov health-state transition model was built to estimate clinical and economic outcomes in HER2-positive breast cancer with or without 12 months trastuzumab adjuvant chemotherapy over a lifetime perspective with annual transition cycles. The model incorporated five health states (disease-free, local recurrence, distant recurrence, cardiac failure, and death). Baseline event rates and 3-year hazard ratio (HR=0.51, IC 95% 0.44–0.59; p<0.0001) were derived from 4-year follow up of the N9831 and NSABP B-31 trial. Costs and utility weights were obtained from the literature and were discounted by 5% annually.Results: The model showed that the utilization of adjuvant trastuzumab treatment in early breast cancer can prolong 0.80 quality-adjusted life-years (QALY), compared with standard chemotherapy, an incremental cost-effectiveness ratio (ICER) of US$ 71,491 per QALY gained.Conclusion: The results suggest that 1-year adjuvant Trastuzumab treatment is not cost-effective in Colombia, using the definition of WHO cost-effectiveness threshold of 3 times GDP per capita.RESUMEN: Introducción. El trastuzumab es un anticuerpo monoclonal de reconocida efectividad para el tratamiento en mujeres con cáncer de mama positivo para HER2. Sin embargo, la mayoría de estudios de costo-efectividad se han llevado a cabo en países desarrollados. Objetivo. Determinar el costo-efectividad del tratamiento adyuvante con trastuzumab en mujeres con cáncer de mama HER2+ en Colombia.Materiales y métodos. Se construyó un modelo de Markov, con ciclos de transición anuales y desde la perspectiva del pagador, para estimar los resultados clínicos y económicos derivados de la administración de trastuzumab en mujeres con HER2 positivo. El modelo incorpora cinco estados de transición: libre de enfermedad, recurrencia local, metástasis, falla cardiaca y muerte. La tasa de eventos y la razón de tazas instantáneas (0,51; IC95% 0,44-0,59; p<0,0001) se derivaron del reporte a cuatro años de los ensayos clínicos controlados N9831 y NSABP B-31. Los costos y las utilidades se estimados a partir de la literatura científica, utilizando una tasa de descuento del 5 % anual.Resultados. El modelo revela que la utilización de trastuzumab como tratamiento adyuvante prolonga la expectativa de vida ajustada por calidad en 0,8 años, en comparación con la quimioterapia sin trastuzumab; a una razón de costo efectividad incremental (sic.) de US$ 71.491 por año de vida ganado ajustado por calidad de vida.Conclusión. El tratamiento con trastuzumab durante un año no es costo-efectivo en Colombia, utilizando la definición de costo-efectividad de la OMS de menos de dos a tres veces el PIB per cápita por año de vida ganado ajustado por calidad de vidaCOL00399027application/pdfengInstituto Nacional de SaludBogotá, Colombiahttps://creativecommons.org/licenses/by-nc-nd/4.0/http://creativecommons.org/licenses/by-nc-nd/2.5/co/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in ColombiaEvaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2- positivo en ColombiaArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionNeoplasias de la MamaBreast NeoplasmsFactor de Crecimiento EpidérmicoEpidermal Growth FactorTrastuzumabAntineoplásicosAntineoplastic AgentsCosto - EfectividadCost effectivenessColombiaColombiaBiomédica41734119BiomédicaPublicationLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/01d2bfc5-4178-4e97-b2df-c3f2dc453283/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADORIGINALBuendíaJefferson_2013_EconomicEvaluationTrastuzumab.pdfBuendíaJefferson_2013_EconomicEvaluationTrastuzumab.pdfArtículo de Investigaciónapplication/pdf768185https://bibliotecadigital.udea.edu.co/bitstreams/a385a91b-298a-4985-a257-2bf7a615631d/download673393701c41ce58c46664b5e441d04eMD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstreams/b77670b1-9ff5-4cbb-b9a3-83cedb153e73/downloadb88b088d9957e670ce3b3fbe2eedbc13MD52falseAnonymousREADTEXTBuendíaJefferson_2013_EconomicEvaluationTrastuzumab.pdf.txtBuendíaJefferson_2013_EconomicEvaluationTrastuzumab.pdf.txtExtracted texttext/plain31720https://bibliotecadigital.udea.edu.co/bitstreams/cebe356d-8f02-4c37-9dc3-c72247f15c57/download8bd47bfafd6e60c330197d8cdd7d5261MD54falseAnonymousREADTHUMBNAILBuendíaJefferson_2013_EconomicEvaluationTrastuzumab.pdf.jpgBuendíaJefferson_2013_EconomicEvaluationTrastuzumab.pdf.jpgGenerated Thumbnailimage/jpeg14385https://bibliotecadigital.udea.edu.co/bitstreams/fca94d09-d560-4c31-8806-97b42954ce53/downloadcc054d4caaeaeff98218d9486504bfb1MD55falseAnonymousREAD10495/35721oai:bibliotecadigital.udea.edu.co:10495/357212025-08-24 21:12:00.154https://creativecommons.org/licenses/by-nc-nd/4.0/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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 |